FDA approves first gene therapy treatment of Duchenne muscular dystrophy
It's unfortunate that biotech funding also depends on the same low rate environment that tech does, because while the tech industry has mostly been spinning its wheels on nonsense after the iPhone (like crypto), there's real innovation in biotech.